Furthermore, in the pretargeting experiment, the tumor and pancreas uptake at 1 h post-injection were reduced upon GRPR blockade with a BBN agonist, from 1.19 ± 0.2 to 0.64 ± 0.1%I.D./g and from 0.4 ± 0.11 to 0.25 ± 0.05%I.D./g, respectively. The gene discussed is GRPR; the disease is neoplasm.